Clinical Trial Update: Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease [Phase 1]

View source ↗

Summary

This Phase 1 study evaluates the pharmacokinetics and safety of LY03003 in patients with early-stage Parkinson's disease; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• LY03003

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED